Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCG | P05129 | 3/20 | 1.00 |
| ▸ | PRKCB | P05771 | 3/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 1.00 |
| ▸ | PRKCH | P24723 | 3/20 | 1.00 |
| ▸ | PRKCI | P41743 | 3/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 3/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 3/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | ABL2 | P42684 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cgp-53353 SCHEMBL29766901 | 1.00 | EGFR (1.00) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834604 | 0.92 | EGFR (0.84) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834231 | 0.88 | EGFR (0.77) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834677 | 0.88 | EGFR (0.77) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL27697134 | 0.84 | EGFR (0.72) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834327 | 0.81 | EGFR (1.00) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8833907 | 0.81 | EGFR (0.69) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834183 | 0.81 | EGFR (1.00) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834514 | 0.81 | EGFR (0.69) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834755 | 0.81 | EGFR (0.69) | EGFRSRCPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1016 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| WO-2021069349-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | claimed |
| EP-3804701-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS PORTIONS OF AN ACTIVE SUBSTANCE | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| EP-3804702-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING ACTIVE AGENT, POLYMER AND SURFACTANT | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| US-20070184055-A1 | TREATMENT WITH ANTI-ERBB2 ANTIBODIES | GENENTECH, INC. | 2007-08-09 | — | — | US | claimed |
| US-20060142591-A1 | DAPH analogs and inhibition of protein aggregation | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2006-06-29 | — | — | US | claimed |
| WO-2006047514-A2 | DAPH ANALOGS AND INHIBITION OF PROTEIN AGGREGATION | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2006-05-04 | — | — | WO | claimed |
| EP-0783887-A2 | Topical compositions for the treatment of hyperproliferative skin disease | CIBA-GEIGY AG (CH) | 1997-07-16 | — | — | EP | claimed |
| US-5491144-A | KINASE INHIBITORS, ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-02-13 | — | — | US | claimed |
| EP-0516588-B1 | Substituted diaminophtalimides and analogues | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | EP | claimed |
| EP-0516588-A1 | Substituted diaminophtalimides and analogues | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | claimed |
| EP-4747284-A1 | ACTIVATABLE ROR BINDING AGENTS AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748453-A2 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747282-A1 | ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747283-A1 | TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-5491144-A | KINASE INHIBITORS, ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0516588-B1 | Substituted diaminophtalimides and analogues | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
| EP-0600832-A1 | Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0516588-A1 | Substituted diaminophtalimides and analogues | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142591-A1 | DAPH analogs and inhibition of protein aggregation | DAP3, DAPK1, DAPK3 | EGFR 3637/4885SRC 965/4885PRKD3 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.